Boston Scientific's $1.1 bil. merger agreement with Target Therapeutics puts the interventional neuroradiology segment firmly in the hands of large, diversified medical products firms.
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
The EU is testing a groundbreaking “all-in-one” process for reviewing combined drug and diagnostic trials via a single application for coordinated assessment.
EU countermeasures against US tariffs suggest medtech categories exported to the EU could be targeted for tariffs. MedTech Europe and the German IVDs industry have stressed the negative effects this would have on patient care.
The Development Bank of Wales and London-based Parkwalk Advisors led an investment round of £5m, almost doubling Ceryx Medical's total investment to date.
